2. Metabolic Enzyme/Protease
  3. FXR Acetyl-CoA Carboxylase
  4. Rebaudioside D

Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research.

For research use only. We do not sell to patients.

Rebaudioside D

Rebaudioside D Chemical Structure

CAS No. : 63279-13-0

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Rebaudioside D:

Rebaudioside D Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Rebaudioside D

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research[1][2].

In Vivo

Rebaudioside D (50 mg/kg; p.o.; daily; 12 weeks) reduces obesity in mice with obesity induced by a high-fat high-sugar (HFHS) diet, alleviates hepatic steatosis and lipid peroxidation, decreases circulating LBP levels, and increases the abundance of Faecalibaculum rodentium in the gut microbiota, without impairing glucose homeostasis[1].
Rebaudioside D (0.2 g/L (0.02%); ad libitum access via drinking water; continuous administration for 16 weeks) does not induce obesity, hepatic steatosis or brown adipose tissue dysfunction, nor does it interfere with skeletal muscle metabolism in mice fed a regular diet[1].
Rebaudioside D (0.2 g/L (0.02%); free access via drinking water; ad libitum access; for 16 consecutive weeks) does not exacerbate obesity or hepatic steatosis in male mice fed a high-fat diet. It maintains the expression of thermogenic proteins in brown adipose tissue, reduces several serum lipid and blood glucose parameters, and shifts the gut microbiota toward a more beneficial profile[2].
Rebaudioside D (0.2 g/L (0.02%); ad libitum access via drinking water for 16 weeks) does not increase the expression of hepatic lipogenic proteins in female mice fed a high-fat diet[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 J (8-week-old male, high-fat/high-sucrose diet-induced obesity)[1]
Dosage: 50 mg/kg
Administration: p.o.; daily; 12 weeks
Result: Reduced weight gain significantly at weeks 8 and 10 through 12 compared to HFHS-fed vehicle controls.
Decreased the sum of all white adipose tissues, with a specific reduction in epididymal adipose tissue weight.
Reduced liver triglyceride and cholesterol levels, and decreased hepatic lipid peroxidation (measured by TBARS).
Animal Model: C57BL/6J (male, 8-10 weeks old)[2]
Dosage: 0.2 g/L (0.02%)
Administration: in drinking water; ad libitum; daily for 16 weeks
Result: Showed no significant difference in oral glucose tolerance test AUC, with a non-significant decreasing trend in fasting blood glucose levels compared to HFD controls.
Had a relative abundance of Bacillota phylum of 75.3%, relative abundance of Akkermansia of 8.07%, and relative abundance of Faecalibaculum of 13.57%.
Identified short-chain fatty acid-producing genera including Faecalibaculum, Acetatifactor, and Parabacteroides as biomarkers via LEfSe analysis.
Molecular Weight

1129.15

Formula

C50H80O28
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC([C@@]2(C)[C@](CC[C@]3(CC4=C)[C@@]5([H])CC[C@]4(O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O[C@]7([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@]8([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)C3)([H])[C@@]5(C)CCC2)=O)[C@@H]1O[C@@]9([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O9
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (88.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.8856 mL 4.4281 mL 8.8562 mL
5 mM 0.1771 mL 0.8856 mL 1.7712 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (2.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 98.48%

SDS (393 KB)

COA (261 KB) HNMR (89 KB) CNMR (96 KB) RP-HPLC (116 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 0.8856 mL 4.4281 mL 8.8562 mL 22.1405 mL
5 mM 0.1771 mL 0.8856 mL 1.7712 mL 4.4281 mL
10 mM 0.0886 mL 0.4428 mL 0.8856 mL 2.2141 mL
15 mM 0.0590 mL 0.2952 mL 0.5904 mL 1.4760 mL
20 mM 0.0443 mL 0.2214 mL 0.4428 mL 1.1070 mL
25 mM 0.0354 mL 0.1771 mL 0.3542 mL 0.8856 mL
30 mM 0.0295 mL 0.1476 mL 0.2952 mL 0.7380 mL
40 mM 0.0221 mL 0.1107 mL 0.2214 mL 0.5535 mL
50 mM 0.0177 mL 0.0886 mL 0.1771 mL 0.4428 mL
60 mM 0.0148 mL 0.0738 mL 0.1476 mL 0.3690 mL
80 mM 0.0111 mL 0.0554 mL 0.1107 mL 0.2768 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rebaudioside D Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rebaudioside D63279-13-0FXRAcetyl-CoA CarboxylaseNR1H4ACC, Acetyl Coenzyme A Carboxylaseacetyl-CoA carboxylase3-hydroxy-3-methylglutaryl-CoA reductaselipid metabolismFaecalibaculum rodentiumHFHS-fed obese micediet-induced obesityhigh-fat diet-fed male micechow diet-fed micebile acid homeostasisfarnesoid X receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Rebaudioside D
Cat. No.:
HY-N0468
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.